K2 Launches with USD 50mn Seed Round

Singapore's K2 Therapeutics, founded by MPM BioImpact in 2024, has emerged from stealth with a USD 50 million seed financing. K2's pipeline comprises eight assets spanning antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) at preclinical through clinical stages, sourced through a global search-and-develop model.

The company describes its approach as combining global asset scouting with experienced drug-development leadership, aiming to identify first-in-class and best-in-class candidates irrespective of technology modality or geographic origin.

The USD 50 million seed commitment from MPM BioImpact will fund pipeline expansion and advancement of initial programmes.

Daily News
Regend Launches First Phase III Cell Therapy Study in COPD
2026-09-21
Ultragenyx Places First Therapy for Sanfilippo Syndrome Type A in US
2026-09-21
Nutshell's Covalent NRF2 Molecular-Glue Degrader Clears IND in US
2026-09-18
Sanofi Opens Upgraded Shanghai R&D Innovation Centre
2026-09-18
Arrowhead RNAi Shows Dual Silencing in Mixed Hyperlipidaemia
2026-09-17
Latest Report
2026 TOP-25 Drug Targets
Details